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Introduction
Early detection of cancer significantly improves the probability of a better survival outcome [1] . For example, 5-year survival rates for early stage non-small cell lung cancer (NSCLC) are around 50 times higher compared with late stage disease [2] .
Given the ageing population, and that the cancer burden is set to increase globally [3] , strategies are needed to improve the early detection of cancer. This challenge is acknowledged by the World Health Organization (WHO) [4] , which has adopted a series of strategies to promote early cancer detection. One approach is developing interventions to raise public awareness through education regarding early warning signs of cancer (e.g. a mole that has recently changed), while another relates to cancer screening: typically individuals from healthy populations are tested to identify those who have previously undetected cancer but, as yet, do not exhibit any symptoms. 1 One healthcare setting that potentially has a role in providing both of these early detection approaches is the community pharmacy. Indeed, the WHO has acknowledged that community pharmacists are the most accessible healthcare professionals to the general public [5] . Studies have shown that community pharmacies offer easy and equitable access to healthcare [6, 7] with estimates that, in the UK, 8490 per cent of the population make at least one visit in the course of a year.
Community pharmacies, therefore, appear to be uniquely placed to raise awareness of and screen for cancer. Work has shown people present at community pharmacies seeking care for symptoms which could be indicative of early signs of cancer [8] , yet, despite this potential, there is no comprehensive review of the role and contribution of community pharmacies in early cancer detection.
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This study aimed to systematically review the literature to identify and assess the current evidence for the role of community pharmacies in delivering early cancer detection initiatives
Methods

Sources
The following electronic databases were searched to identify evidence: MEDLINE (Ovid), EMBASE (Ovid), CINAHL (EbscoHost) and PsycINFO (EbscoHost). The search period was from inception of the databases to February 2015. The terms used in the search strategy were related to cancer, community pharmacy and intervention (Appendix 1). The search strategy was modified when appropriate to suit syntax requirements; no MeSH terms were used. No limit was placed on study type, publication, date and language in the search strategy. The reference lists of the included studies were hand searched to identify relevant studies.
The review was designed and carried out following established guidelines on good conduct and reporting of systematic reviews [9, 10] ; the protocol was registered with PROSPERO [11] , registration number 2014:CRD42014009092.
Study selection
To be included in the review, studies had to meet the following criteria:
1. Setting: include or take place within a community pharmacy. In this review community pharmacy was defined as pharmacy that is based in the community (not in a hospital, clinic or online) and is accessible to all; 2. Population: the general public accessing a cancer education or screening intervention; 3. Study type: all study types were included; 4. Intervention: patient-focused cancer education and raising awareness over early cancer symptoms, cancer screening and/or detection; 5. Outcomes: study outcomes were conceptualised in accordance with the framework proposed by Hardeman et al [12] . This framework contains four categories: determinants of behaviour (e.g. increased patient knowledge), behavioural outcomes (e.g. reducing exposure to cancer risk factors), physiology and biochemical outcomes (identification of patients with premalignant disease) and health outcomes (incidence rates of cancer).
Any study that was not set in a community pharmacy was excluded from the review (e.g. a pharmacist working in an outpatient clinic). Interventions that solely sought to educate the community pharmacy team about cancer awareness or did not specifically include patients were also excluded. Studies that were reported as abstracts were also excluded from the review.
The initial screening of search titles and abstracts was undertaken by one researcher(LL) with a ten per cent sample checked by a second researcher(AT); any disagreement was discussed and, if agreement could not be reached, consensus was 4 reached with a third researcher(AH). The full text version of selected studies were independently screened for by two researchers(LL, AT); data extraction was done independently by two researchers (LL, HN) using a template based on the EPOC data extraction form [13] . Differences in data extraction were resolved through discussion and, if consensus was not reached, the project lead was consulted(AT).
Results
Literature search
In total 2772 articles were identified, 2767 hits were generated through database searches and further five articles were identified through hand search. After duplicates were removed, 2451 studies were screened based on title. Of these, 644 were screened for both title and abstract, which resulted in a full paper screen of 32 articles.
In total, ten articles were included in the review (Figure 1 ). 
Analysis
The studies identified for the review were strongly heterogeneous, thus, it was not feasible to pool results and undertake a meta-analysis. A narrative approach to synthesising the results was adopted. The data used for the synthesis included: type of cancer, study design, population, location, study objectives, outcome measures and outcomes. The categories listed in the TIDieR recommendations for better reporting of interventions, were used to summarise the interventions described in the studies [14] . 
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Quality appraisal
The studies were assessed for quality using the EPHPP Quality Assessment Tool for Quantitative Studies [15] recommended by Cochrane. The global quality scores, based on the individual component scores, divided the studies to strong (n=1) [16] , moderate (n=5) [17] [18] [19] [20] [21] and weak (n=4) [22] [23] [24] [25] . The study components most commonly assessed as weak were confounders and the data collection methodology.
Description of studies
Ten studies were included in the review, these are described in Table 1 . The studies were categorised according to the chart of study types for inclusion in EPOC reviews [26] ; one was a randomised controlled trial [21] , one was a cluster randomised trial [24] , one was a non-randomised trial [22] and the remainder were non-comparative studies [16-20, 23, 25] .
Study locations were the US (n=5) [17] [18] [19] [20] 24] , Australia (n=2) [22, 23] , Germany (n=1) [16] , Italy (n=1) [21] and South Korea(n=1) [25] . The number of participants included in the studies ranged from 91 [23] to 14,041 [21] , while the duration including follow up ranged from four weeks [19] to two years [16] .
Cancer types
Types of cancer targeted by the studies included colorectal cancer (n=4) [19, [22] [23] [24] ; colorectal and prostate cancer (n=1) [17] ; prostate cancer (n=1) [16] ; breast cancer (n=2) [18, 25] ; cervical cancer (n=1) [21] ; and breast and cervical cancer (n=1) [20, 21] .
Participants
The total number of participants in the studies was 25,449, ranging from 91 [23] to 14,041 [21] . Four of the studies were aimed exclusively at women (those for breast and cervical cancer), two at men (those for prostate cancer) and four at both sexes.
Three of the studies targeted specific populations: one focused on women living in medically underserved communities [20] , one on women who were non-responders to a screening invitation [21] , and one on men with untreated or uncontrolled health risks or who were due a physical examination [17] .
Study outcomes
The Hardeman causal model was used to categorise the outcomes [12] . All ten studies reported outcome measures relating to the domain of behavioural determinants; increasing awareness and knowledge (n=7) [16-20, 24, 25] ; recommending referral (n=3) [21] [22] [23] . Outcomes of four studies were identified as influencing patient's behavior [16, 17, 19, 20] . Physiological and biochemical outcomes were measured in four studies (FOB n=2 [19, 24] , PSA n=1 [16] , Pap/HPV DNA n=1 [21] ) and health outcomes (cancer diagnosis) in two [16, 19] .
Educational interventions
Four of the studies were aimed at educating the patients [18, 20, 24, 25] . Of these, three were specifically focused on educating women about breast and ovarian cancer.
These included a city wide education programme focusing on reducing breast cancer 'myths' [25] and a community intervention to increase the uptake of screening for breast and ovarian cancer in medically underserved areas [20] . Third study provided education and training on breast self-examination (BSE), clinical breast examination (CBE) and mammograms, and provided risk assessment screening [18] . The fourth 8 study, on colorectal cancer, compared the outcomes between providing patients educational handouts and advice or giving patients FOB test kits [24] .
Screening interventions
Eight of the studies undertook screening [16] [17] [18] [19] [21] [22] [23] [24] . Four of the studies used test kits, of which, two were FOB tests [19, 24] , one was a PSA blood test [16] and one used Pap and HPV DNA tests [21] . Three of these studies were large scale screening programmes (n=2,119 [16] , n=7,794 [19] , n=14,041 [21] ) and one was a smaller pilot (n=133) [24] .
Four studies provided screening through questionnaires or checklists [17, [22] [23] [24] . All the screening tools were previously validated or were constructed from previously validated instruments. The Patient Consultation Questionnaire (PSQ) [27] , for identifying patients at risk of colorectal cancer, was used by two of the studies [22, 23] , while a Breast Cancer Risk Assessment Tool (Gail model) [28] was used in one study. Another study combined a number of existing tools, including assessments for prostate cancer [29] and colorectal cancer [30] , to form a Men's Health Risk Assessment Tool (MHRAT) [17] ; however, this tool was not checked for validity or reliability.
Three studies identified patients at increased risk of various developing cancers [17, 18, 23] . The study utilising the MHRAT assessed 40 per cent of participants to be at risk of developing prostate cancer and 24 per cent at risk of colon cancer [17] .
Similarly, a breast cancer education and screening intervention found 15 per cent of the participants to be at increased risk of developing breast cancer [18] , whilst a screening study for bowel cancer found that 8.7 per cent of those presenting at community pharmacies with bowel symptoms were high risk [23] .
9
Two studies identified the percentage of people attending a follow up appointment after receiving an initial positive screening test result (23.4% for PSA test [16] , 59% for FOB test [19] ). For the studies using screening tools, the percentage of participants who acted on the recommendation of a referral ranged from 8.8 per cent [23] to 48.7 per cent [17] .
Cancer detection
A study using a FOB test for colorectal cancer reported one abnormal test result; no further details on diagnosis was given [24] . The cervical screening RCT compared posting self-sampling tests to non-responders and making the tests available through community pharmacies with the standard practice of a reminder letter; however, the test results were presented together for both of the experimental conditions, therefore it is not known how many of the test kits distributed through pharmacies had a positive test result [21] . Two other studies followed patients throughout the screening process to confirm or exclude a cancer diagnosis. In a prostate screening study, involving all 28 pharmacies in the city, 15 per cent of the PSA test results were positive (PSA >4.0ng/ml) [16] and prostate carcinoma was confirmed in 14 cases, corresponding to an incidence rate of 650 cases per 100,000 men tested. In a colorectal cancer screening, of the 1337 participants assessed as high risk, 23 (2%) were diagnosed with colorectal cancer, of which 20 were early stage [19] .
Discussion
This review presents the available evidence on using community pharmacies as a setting to deliver early cancer detection interventions through screening and education. The review shows, it is possible to recruit patients to such interventions through a community pharmacies, and to identify patients who are at an increased risk of developing cancer. These findings are timely, as recent draft NICE guidance acknowledges thousands of people die every year because of a late cancer diagnosis and thus recommends more people should be referred for cancer testing [31] . Our results suggest that community pharmacies could make a significant contribution to this activity. The potential for increasing community pharmacy involvement in this area has been noted by an early detection collaboration (the ACE programme), which seeks to increase the evidence base around the best practice in early detection, and one of the activity clusters specifically focuses on pharmacy-led initiatives [32] .
Due to the heterogeneity of the study outcomes, performing a meta-analysis was not possible; we were limited to reporting our findings as a narrative synthesis and acknowledge this as a limitation of our review. Also, as we restricted our review to interventional studies, qualitative studies examining participants' views on using community pharmacies for such interventions, were excluded. Clearly, for patients to engage in early cancer detection interventions within community pharmacy settings, it is important that they are perceived as worthwhile, appropriate and valuable.
However, even though the selection criteria for the review were specifically for interventional studies, some of the studies did include a qualitative aspect and indicated a positive perceptiongood reception of the amongst the participants towards community pharmacy based interventions. One study surveyed participants' perceptions as part evaluating the screening intervention, finding that the participants were enthusiastic about receiving colorectal cancer education and screening from community pharmacists, as they felt that pharmacies were a trustworthy source of information [24] . Another study reported increased confidence levels amongst participants in their ability to perform a breast self-examination following the 11 pharmacy intervention [18] . Furthermore, previous qualitative work has shown that, in the context of wider public health initiatives, patients view community pharmacists as appropriate providers of such services and, of those that accessed such services, satisfaction levels were found to be high [33] .
In the light of the demand to increase community pharmacy involvement in the delivery of wider public health services [6, [34] [35] [36] [37] , there is a growing body of literature in this area. Indeed a relatively recent systematic review [38] exploring the role of community pharmacies in screening for major diseases concluded it is feasible to screen patients in this setting, but more studies were needed to ascertain the effectiveness and economic benefit of such interventions; of note, this work only identified three studies that were included in our review. Nonetheless, our study supports this work, and shows that the community pharmacy is a feasible setting to deliver screening and educational interventions in relation to the early detection of cancer.
Given the easy and equitable access of community pharmacies, it is possible that delivering early cancer interventions from community pharmacies could also potentially have an impact on health inequalities, with a recent study showing access to community pharmacies is greatest in areas of high deprivation -the so-called positive pharmacy care law [6] . Indeed, given the evidence that supports an inverse correlation between socioeconomic status and incidence and mortality of some cancers, cancer-related inequalities represent a significant challenge for current healthcare systems. Generally, the studies identified in our review were aimed at the general public rather than specifically targeting patients from deprived communities; the socioeconomic status of patients' accessing the interventions were not reported among the studies. One small-scale study did, however, focus on low and moderate
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income women living in a medically underserved area and showed that community pharmacies could be used to identify patients at risk of breast and cervical cancer, and to refer them on for further investigation [20] . It is not clear if, or how, this study impacted on health inequalities or if this kind of intervention could be applied to initiatives for other cancers.
Even though the outcomes of the interventions were encouraging, not enough details were given, to get a comprehensive understanding of the interventions that would allow for replication. In general, the practical elements of the interventions were poorly reported, especially in the areas of the delivery, education and fidelity. This lack of detail highlights the need for checklists, such as the TIDieR guide, developed by Hoffman and colleagues, to enable detailed reporting of interventions [14] .
Assessing the interventions against the TIDieR categories, it was apparent that the mode of delivery, tailoring and details of modifications were not reported; information about the provider, including expertise, background and training were also limited. The quality and depth of reporting within the included studies is, at present, insufficient to enable others to effectively design and reproduce the interventions, which possibly has implications for the commissioning of future services in this area.
None of the studies explicitly indicated a theoretical framework underpinning the design or delivery of the intervention. This is not to say that the interventions were developed without thought, previous work in the area guided the development of the chosen approach. As many of the interventions were pilots, the focus was on the specific cancers and how screening and education had been undertaken in the past.
However, taking the theoretical aspect into account when planning interventions, 13 would enable greater interplay between practice and theoretical evidence and the advancement of both through the recognition of their interdependent nature [39] .
Beyond improving the reporting of interventions, there should also be more focus on capturing the impact of the studies in terms of actual benefit to patients. On the whole, the included studies did not follow the participant through their care pathway and ascertain if a cancer diagnosis was made, and if it was made, the time taken to reach a diagnosis or how the intervention impacted on overall patient survival was not ascertained. We do, however, acknowledge that several of the studies included within the review were not designed to follow up patients in terms of diagnosis or cancerrelated morbidity. Furthermore, it is also not understood whether interventions delivered through community pharmacies target a different patient group than what is currently being reached through other providers. In view of these limitations, further work in this area, exploring how such interventions affect the time taken to reach a cancer diagnosis or patient survival are warranted.
Conclusion
There is scope to use community pharmacies as a setting to deliver education and screening early cancer detection interventions. Current evidence shows it is feasible to recruit patients in this setting, but more studies are warranted to demonstrate how these interventions impact on the time taken to reach a cancer diagnosis and patient outcome in comparison to other providers.
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